CD274 and neoplasm: Analysis of tumor infiltrating lymphocytes revealed an increase of infiltrated T cells in the tumor microenvironment, suggesting that the strategy of using a tumor-targeted PD-L1-blocking bispecific antibody can enhance anti-tumor activity of anti-PD-L1 therapy alone (Zhang et al., 2019).